$21.10 1.30 (+6.57%)
11/6/2009 4:00 PM

Pharmasset, Inc. (VRUS)

CAPS Rating: 2 out of 5

A clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections.

Current Price $21.10 Mkt Cap $593.98M
Open $19.64 P/E Ratio 0.00
Prev. Close $19.80 Div. (Yield) N/A (N/A)
Daily Range $19.64 - $21.21 Volume 61,766
52-Wk Range $7.62 - $24.60 Avg. Daily Vol. 114,000

VRUS News and Commentary

Related News and Articles

Caps

How do you think VRUS will perform vs the S&P 500?

Add Stock to Watchlist

All Members

56 Outperform
29 Underperform
 

All-Star Members

14 Outperform
15 Underperform
 

Wall Street

12 Outperform
0 Underperform
 

Top VRUS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFBreakerBrian (99.26)
Submitted March 31, 2008

Top HCV polymerase inhibitor on the block right now. Look for combo treatments with the protease inhibitors. Roche is the ideal partner for any anti-HCV drugmaker... Plus a little bit of extra pipeline to boot although not as exciting as its anti-HCV… More

0 Comments | Reply | Report this Post

majakblue (< 20)
Submitted January 19, 2008

Ridiculous run-up. Typical pharma wannabe IPO. It probably will outperform initially as investors raise the price artificially high, and then tank as it becomes clear that the company will not be profitable for years to come if ever. It would be a… More

0 Comments | Reply | Report this Post
VRUS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about VRUS.

Recs

0
Member Avatar ScreenerStizBear (< 20) Submitted: 6/26/2008 2:26:22 PM : Underperform Start Price: $19.04 VRUS Score: -25.14

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar Rep07 (97.04) Submitted: 6/17/2008 11:44:40 AM : Underperform Start Price: $20.10 VRUS Score: -23.33

Show me why this is worth so much. We're into a bear market so it better be good. Meanwhile ima short this sucka

Report this Post 0 Comments | Reply | Permalink

Recs

2
Member Avatar TMFBreakerBrian (99.26) Submitted: 3/31/2008 1:37:35 PM : Outperform Start Price: $18.01 VRUS Score: +33.35

Top HCV polymerase inhibitor on the block right now. Look for combo treatments with the protease inhibitors. Roche is the ideal partner for any anti-HCV drugmaker... Plus a little bit of extra pipeline to boot although not as exciting as its anti-HCV drug.

Report this Post 0 Comments | Reply | Permalink
View All 10 Pitches »

Leaderboard

Find the members with the highest scoring picks in VRUS.

Score Leader

zzlangerhans

zzlangerhans (99.36) Score: +207.99

Took a while to knock that other guy out of here. He timed the last spike a lot better than I did.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
testosteron < 20 7/30/2007 Outperform 5Y $10.50 +100.95% -23.08% +124.03
strayrider < 20 7/23/2007 Outperform 1Y $10.99 +91.99% -26.86% +118.85
bflochp < 20 9/12/2007 Outperform 3Y $12.00 +75.83% -23.43% +99.27 1 Comment
Paratext 72.79 9/12/2007 Outperform 5Y $12.00 +75.83% -23.43% +99.27
Swanyandblondie < 20 9/11/2007 Outperform 1Y $12.00 +75.83% -22.89% +98.72
jthe4th 31.11 9/11/2007 Outperform 3Y $12.00 +75.83% -22.89% +98.72 1 Comment
portefeuille2 99.85 3/10/2009 Outperform NS $8.49 +148.38% +51.62% +96.76
SSPXXX < 20 6/8/2009 Outperform 5Y $10.19 +107.07% +15.35% +91.72
mommaneedsmoola < 20 4/2/2009 Outperform NS $9.74 +116.63% +30.17% +86.47
CaptainFiveBaggr 99.82 6/10/2009 Outperform 5Y $10.86 +94.29% +13.38% +80.91
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackRWBaird 85.02 9/9/2009 Outperform NS $20.25 +4.20% +4.51% -0.31
TrackWedbush < 20 3/18/2009 Outperform NS $9.35 +125.67% +40.15% +85.51
TrackThinkEquity 69.79 1/27/2009 Outperform NS $10.75 +96.28% +29.59% +66.69
TrackRothCapital 75.81 12/5/2008 Underperform NS $12.50 -24.64% -13.71% +10.93 3/3/2009 @ $9.42
TrackCowenandCo 74.62 10/29/2008 Outperform NS $16.43 +28.42% +17.76% +10.66
TrackLazardCapit < 20 10/21/2008 Outperform NS $21.55 -2.09% +13.32% -15.40
TrackLeerinkSwan 84.26 7/28/2008 Outperform NS $18.58 +13.56% -11.92% +25.49
TrackPacificGrow 90.86 5/21/2008 Outperform NS $17.74 +18.94% -20.46% +39.40
TrackUBS 86.41 4/2/2008 Outperform NS $20.00 +5.50% -19.06% +24.56
TrackMerriman < 20 3/11/2008 Outperform NS $15.60 +35.26% -14.59% +49.85
TrackSusquehanna 74.76 12/7/2007 Outperform NS $14.15 +49.12% -25.88% +74.99
TrackUBS 86.41 6/11/2007 Outperform NS $8.85 +137.85% -9.54% +147.39 2/19/2008 @ $21.05
TrackStifel 94.70 6/8/2007 Outperform NS $8.75 +128.57% -4.69% +133.26 1/8/2008 @ $20.00
TrackJMP < 20 6/7/2007 Outperform NS $8.90 +137.08% -25.27% +162.35
TrackBofASec 93.50 6/6/2007 Outperform NS $9.00 +134.44% -25.93% +160.37

Featured Broker Partners